Posts by: Patricia Inacio, PhD

News

New research unveils how two molecules, protein complexes called S100A8 and S100A9, are regulated in order to limit an inflammatory responses to sites where they are needed, preventing the ... Read more

June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen ... Read more

May 21, 2018May 21, 2018

Immuron’s IMM-124E Significantly Eases Symptoms of Chronic Colitis in Mouse Model, Company Reports

News

Immuron’s investigational therapy IMM-124E significantly reduced intestinal inflammation in mice models of chronic colitis, the company reports. These results add to previous preclinical evidence showing the therapy to also ... Read more

April 23, 2018April 23, 2018

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

News

Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a ... Read more

April 18, 2018April 18, 2018

Exposure to Livestock Farms Alone Doesn’t Increase Risk of IBD, Dutch Study Suggests

News

Researchers in the Netherlands found that exposure to livestock farms alone carries little risk for developing inflammatory bowel disease (IBD). Their findings suggest that residents in livestock-dense areas may ... Read more

April 11, 2018April 11, 2018

Oral PL-8177 Reduces Gut Inflammation in Rat Model of IBD, New Results Show

News

Palatin Technologies‘, investigational PL-8177, taken orally, reached the large intestine and colon, resulting in significantly reduced inflammation and damage in a bowel inflammation rat model. The poster on the ... Read more

March 12, 2018March 12, 2018

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

News

An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain ... Read more

March 5, 2018

Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies

News

Real-world treatment results showed that Takeda’s Entyvio (vedolizumab) was better than an anti-tumor necrosis factor-alpha therapy at alleviating moderate to severe ulcerative colitis or Crohn’s disease, according to several studies. ... Read more

January 31, 2018January 31, 2018

More Severe IBD Boosts Risk for Non-alcoholic Fatty Liver Disease, Italian Study Suggests

News

The risk that inflammatory bowel disease (IBD) patients will develop non-alcoholic fatty liver disease (NAFLD) increases as IBD worsens, according to Italian researchers. Their study “Non-alcoholic fatty liver disease ... Read more

January 26, 2018January 26, 2018

Researchers Target Specific Gut Bacteria to Control Inflammation in Mice Study of Colitis

News

Researchers at UT Southwestern Medical Center have discovered a way to target a specific population of bacteria that promotes gut inflammation in mice. While more studies are needed, they ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Protein Complex May Offer Way of Limiting Inflammatory Reactions, Study Suggests

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

Immuron’s IMM-124E Significantly Eases Symptoms of Chronic Colitis in Mouse Model, Company Reports

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

Exposure to Livestock Farms Alone Doesn’t Increase Risk of IBD, Dutch Study Suggests

Oral PL-8177 Reduces Gut Inflammation in Rat Model of IBD, New Results Show

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies

More Severe IBD Boosts Risk for Non-alcoholic Fatty Liver Disease, Italian Study Suggests

Researchers Target Specific Gut Bacteria to Control Inflammation in Mice Study of Colitis

Pin It on Pinterest